How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,476 results for

Tocolytic

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor

Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02989519 Recruitment Status : Completed First Posted : December 12, 2016 Last Update Posted

2016 Clinical Trials

22. The combination tocolytic effect of MgSO<sub>4</sub> and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. (Abstract)

The combination tocolytic effect of MgSO4 and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. Preterm birth at <37 weeks of gestation is the most common and costly complication of pregnancy and remains the leading cause of neonatal morbidity, death, and reduced achievement in surviving infants. Magnesium sulfate is 1 class of tocolytics for threatened preterm labor; however, its clinical efficacy has been questioned. Twin pregnancies (...) reversed in twins (P<.01).Magnesium sulfate is equipotent in suppressing contractions in singleton and twin myometrium. Oxytocin (0.5 nmol/L) significantly reduces the tocolytic potency of magnesium sulfate, which may explain, in part, magnesium sulfate's poor efficacy in vivo; however, this can be reversed partially by the use of an oxytocin receptor antagonist. Combination tocolysis that involves oxytocin receptor antagonists requires further investigation.Copyright © 2016 Elsevier Inc. All rights

2016 American Journal of Obstetrics and Gynecology

23. Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature

Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

24. Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor

Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02538718 Recruitment Status : Recruiting First Posted : September 2, 2015 Last

2015 Clinical Trials

25. ATP-sensitive potassium channels modulate in vitro tocolytic effects of β2-AR agonists on uterine muscle rings in rats in early but not in late pregnancy Full Text available with Trip Pro

ATP-sensitive potassium channels modulate in vitro tocolytic effects of β2-AR agonists on uterine muscle rings in rats in early but not in late pregnancy To investigate whether ATP-sensitive potassium (K(ATP)) channels modulate the tocolytic effect of β2-adrenergic receptor (β2-AR) agonists (ritodrine and salmeterol) in early-pregnant (day 6) and late-pregnant (day 22) rat uterus in vitro, in order to examine the relation between the K(ATP) channel sulphonylurea-binding regulatory subunit (SUR (...) ) expression and pharmacological reactivity of β2-AR agonists.The tocolytic effects of ritodrine and salmeterol (10(-10)-10(-5) M) on spontaneous rhythmic contractions were investigated cumulatively, alone, or in the presence of the K(ATP) channel blocker glibenclamide (10(-6) M) and the K(ATP) channel opener pinacidil (10(-9)-10(-7) M) after 5-min preincubation.β2-AR agonist induced myometrial relaxation was inhibited by glibenclamide and enhanced by pinacidil on day 6, when SUR1 expression levels were

2015 Croatian medical journal

26. The Effects of Progesterone Therapy on the Gestation Length and Reduction of Neonatal Complications in Patients who had Received Tocolytic Therapy for Acute Phase of Preterm Labor. Full Text available with Trip Pro

The Effects of Progesterone Therapy on the Gestation Length and Reduction of Neonatal Complications in Patients who had Received Tocolytic Therapy for Acute Phase of Preterm Labor. While tocolytic therapy can halt the process of delivery, some patients return before the 37th week of pregnancy with recurrence of preterm labor signs.This study was designed to evaluate the efficacy of progesterone in the prolonging of gestation and reduction of neonatal complications.In a clinical trial in 2010 (...) that progesterone can significant reduce the rate of recurrent preterm labor and the several possible neonatal complications among women who had treated with tocolytics to suppress the acute phase.

2014 Iranian Red Crescent medical journal Controlled trial quality: uncertain

27. Medical Transfer of Patients in Preterm Labor: Treatments and Tocolytics. (Abstract)

Medical Transfer of Patients in Preterm Labor: Treatments and Tocolytics. Abstract Objective. To examine the epidemiology, effectiveness, and safety of tocolytics, and the variation in use of standard treatments and predictive testing for women in preterm labor (PTL) transported to tertiary care. Methods. This was a health record review of consecutive PTL patients (<38 weeks gestation) transported to a tertiary care facility by Ontario's air and land critical care transport service between (...) January 1, 2006 and January 1, 2011. The primary outcome was the effectiveness of tocolytics in decreasing the frequency of contractions and incidence of delivery. Secondary outcomes included the type of tocolytics used, adverse events (defined a priori), use of standard treatments (corticosteroid, antibiotic), and use of predictive tests (cervical length measurement, fetal fibronectin). We report descriptive statistics and relative risk of contractions decreasing with tocolytics with 95% confidence

2014 Prehospital emergency care

28. Nifedipine versus Terbutaline, Tocolytic Effectiveness and Maternal and Neonatal Adverse Effects: a Randomized, Controlled Pilot Trial. (Abstract)

Nifedipine versus Terbutaline, Tocolytic Effectiveness and Maternal and Neonatal Adverse Effects: a Randomized, Controlled Pilot Trial. Although previous evidence suggests advantages of nifedipine over terbutaline as tocolytic agents, in some jurisdictions, terbutaline is approved for use and nifedipine is not. In women in preterm labour, we compared the impact of terbutaline versus nifedipine on inhibition of uterine contractions, preterm birth, neonatal sepsis, intracranial haemorrhage (...) of terbutaline increased tremor (76.4% versus 0%), nausea (58.8% versus 9.4%) and dizziness (29.4% versus 6.25%). The total number of side effects, and the proportion of women experiencing one or more side effects, proved greater with terbutaline. In this study, terbutaline and nifedipine performed similarly in their tocolytic effects. Each drug has specific side effects, although overall, nifedipine was associated with fewer adverse effects. © 2014 Nordic Association for the Publication of BCPT (former

2014 Basic & clinical pharmacology & toxicology Controlled trial quality: uncertain

29. Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour

Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02068404 Recruitment Status : Unknown Verified July 2015 by Chantal Csajka, Centre

2014 Clinical Trials

30. Nanovectors to Prevent Placental Passage of Tocolytic Agents

Nanovectors to Prevent Placental Passage of Tocolytic Agents Nanovectors to Prevent Placental Passage of Tocolytic Agents - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nanovectors to Prevent Placental (...) Passage of Tocolytic Agents The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02199756 Recruitment Status : Recruiting First Posted : July 24, 2014 Last Update Posted : November 2, 2018 See Sponsor: The University of Texas

2014 Clinical Trials

31. A comparison of three tocolytics for preterm labor: a randomized clinical trial. (Abstract)

A comparison of three tocolytics for preterm labor: a randomized clinical trial. To compare the efficacy and maternal side effects of nifedipine (N), magnesium sulfate (M), and indomethacin (I) for acute tocolysis.In this single center randomized trial, women in preterm labor 24-32 weeks' gestation received intravenous M, oral N, or I suppositories. The primary outcomes of interest were arrest of preterm labor (>48 h, ≥7 days), gestational age at delivery, and maternal side effects.Over a 38 (...) of pulmonary edema in the M group and one with plural effusion in the N group.There were no differences in efficacy or in major maternal safety issues between the three tocolytic agents. Since there is no FDA approved tocolytic to treat preterm labor, clinicians should use the tocolytic that has afforded them the best results with the least maternal/neonatal side effects.

2014 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians Controlled trial quality: uncertain

32. Tocolytic indomethacin: effects on neonatal haemodynamics and cerebral autoregulation in the preterm newborn. (Abstract)

Tocolytic indomethacin: effects on neonatal haemodynamics and cerebral autoregulation in the preterm newborn. Indomethacin has vasoactive properties in cerebral and systemic vascular beds, and it improves cerebral autoregulatory ability. We speculated that tocolytic indomethacin will improve cerebral autoregulatory ability in the very preterm infant in early postnatal life.Eighteen stable preterm infants gestational age (GA) 25.3-29.6 weeks, birth weight (BW) 660-1430 grams), whose mothers had (...) received 50-150 mg of tocolytic indomethacin within 24 h before birth, and 18 individually matched controls (GA 25.0-29.7 weeks, BW 700-1390 grams) were studied four times for 15 min in the first 24 h of life. Autoregulation was assessed by determining correlations between mean arterial blood pressure (MABP (mm Hg)) and near-infrared spectroscopy-monitored cerebral oxygenation (rScO2).MABPs were significantly higher in the indomethacin infants than in the control infants (p=0.03). A decreased ability

2013 Archives of Disease in Childhood. Fetal and Neonatal Edition

33. Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic Combinations Full Text available with Trip Pro

Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic Combinations Dihydropyridine Ca2+ channel blockers (CCBs) are widely accepted in the treatment of premature labour. Their mechanism of action in tocolysis involves the blockade of L-type Ca2+ channels, influenced by the Ca2+-activated K+ channels, beta-adrenergic receptors (β-ARs) and sexual hormones. In clinical practice, most experience has been gained with the use of nifedipine, whose (...) efficacy is superior or comparable to those of β-agonists and oxytocin antagonists. Additionally, it has a favourable adverse effect profile as compared with the majority of other tocolytics. The most frequent and well-tolerated side-effects of CCBs are tachycardia, headache and hypotension. In tocolytic therapy efforts are currently being made to find combinations of tocolytic agents that yield better therapeutic action. The available human and animal studies suggest that the combination of CCBs

2013 Pharmaceuticals

34. Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery

Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery (UTM/2012) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01796522 Recruitment Status : Withdrawn (have been published new studies

2013 Clinical Trials

35. Tocolytic

Tocolytic Tocolytic Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Tocolytic Tocolytic Aka: Tocolytic , Tocolysis II. Indications III (...) . Contraindications (See specific medications) or lethal fetal anomaly <100 >180 or Maternal bleeding with hemodynamic instability Maternal Systolic <90 mmHg Maternal cardiopulmonary symptoms (e.g. , ) IV. Preparations: Preferred Tocolytics ral Indications Stops labor for 24-48 hours Allows maternal transport and doses Load: 6 grams bolus IV over 20 min (Very high dose!, some protocols use 4 g load) Maintenance: 2 grams/hour IV infusion (max: 3 g/h) Must follow protocols for patient safety Tocolytic

2015 FP Notebook

36. Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. Full Text available with Trip Pro

Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. Vaginal progesterone has a potential beneficial effect in postponing of preterm labor by suppression of prostaglandins cascades. Although different studies evaluated the use of progesterone for preterm birth, the exact effect of which on prolongation of pregnancy remains unclear. Seventy two women who underwent preterm labor were managed by magnesium sulfate. Then they were randomly assigned to continue pregnancy

2012 ISRN obstetrics and gynecology Controlled trial quality: uncertain

37. The tocolytic role of nifedipine in preventing preterm labour pain. (Abstract)

The tocolytic role of nifedipine in preventing preterm labour pain. This study was undertaken to evaluate the efficacy of oral nifedipine to reduce labour pain in patient with preterm labour, to complete the doses of steroids in lung maturity and in utero transfer to the Neonatal Intensive Care Unit (NICU) and to evaluate the maternal adverse effects and neonatal outcome. Diagnosed cases of preterm labour (between 24 to 34 weeks gestation) were randomly selected. Among them 50 patients were (...) nifedipine in patients with preterm labour pain as Tocolytic therapy has significantly prolonged pregnancy with lesser neonatal problems and fewer maternal adverse effects.

2012 Mymensingh medical journal : MMJ Controlled trial quality: uncertain

38. The use of tocolytic therapy in a pregnant trauma patient

The use of tocolytic therapy in a pregnant trauma patient BestBets: The use of tocolytic therapy in a pregnant trauma patient The use of tocolytic therapy in a pregnant trauma patient Report By: Helene Svinos - Medical Student Search checked by Anna O' Malley - Medical Student Institution: University of Manchester Date Submitted: 9th June 2008 Date Completed: 11th March 2009 Last Modified: 11th March 2009 Status: Green (complete) Three Part Question In a [pregnant trauma patient] does (...) [tocolytic therapy] improve [outcome for mother and foetus]? Clinical Scenario A pregnant woman of 32 weeks gestation is admitted to the ED after a fall. She has blunt abdominal trauma and is having what seem to be uterine contractions. You wonder whether you start tocolytic therapy to try to prevent or delay a premature delivery and so prevent some of the possible complications for both mother and baby. Search Strategy Medline 1950 to November week 1 2008 using Ovid Interface EMBASE 1980-2008 Week 1

2009 BestBETS

39. Inhibition of uterine contractility with various tocolytics with and without progesterone: in vitro studies. (Abstract)

Inhibition of uterine contractility with various tocolytics with and without progesterone: in vitro studies. Various tocolytics are used to suppress uterine contractility in patients in preterm labor. Progesterone (P4) is used in patients at high risk for preterm delivery. In this study, we evaluated the effects of various tocolytics with and without P4 to examine effects on uterine contractility.Uterine tissues (n = 280) from women undergoing cesarean at term were exposed in vitro to various

2011 American Journal of Obstetrics and Gynecology

40. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. (Abstract)

Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. To assess the efficacy of vaginal micronized natural progesterone as a tocolytic and in maintenance therapy during threatened preterm birth.Eighty-three women with symptoms of threatened preterm birth were either randomized to study groups receiving tocolytic treatment combined with intravaginal micronized natural progesterone (200 mg daily) or to a control group receiving only tocolysis.Micronized natural (...) progesterone treatment resulted in a prolonged latency period of 32.1 ± 17.8 versus 21.2 ± 16.3 days in the control group and heavier birth weights of 2,982.8 ± 697.8 g versus 2,585.3 ± 746.6 g. No significant differences were found between the groups in admission to the neonatal intensive care unit, stay at the neonatal intensive care unit, need for a mechanical ventilator, respiratory distress syndrome or neonatal sepsis.The treatment of threatened preterm birth with tocolytics combined with intravaginal

2011 Gynecologic and obstetric investigation Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>